• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy

byNeel MistryandTeddy Guo
December 6, 2022
in Cardiology, Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Bivalirudin during percutaneous coronary intervention plus high-dose infusion after demonstrated decreased all-cause mortality compared to heparin monotherapy.

2. Risk of major bleeding was marginally greater in the heparin monotherapy group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Percutaneous coronary intervention (PCI) is used as first-line treatment in patients with ST-segment elevation myocardial infarction (STEMI). Although studies show that bivalirudin, a direct-acting thrombin inhibitor, may be used to reduce bleeding, there has been conflicting evidence with differences in methodology. This randomized trial aimed to compare the safety and efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevated myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The primary outcome was a composite of all-cause mortality and major bleeding, as defined by Bleeding Academic Research Consortium (BARC) types 3-5. Patients were randomly assigned to either intervention group and received bivalirudin with a post-PCI high-dose infusion or unfractionated heparin monotherapy. According to study results, patients randomized to bivalirudin demonstrated significantly decreased all-cause mortality and major bleeding at 30 days. This study was strengthened by a large sample size, adding to its validity.

Click to read the study in The Lancet

Relevant Reading: Bivalirudin versus Heparin Monotherapy in Myocardial Infarction

In-depth [randomized-controlled trial]: Between Feb 14, 2019, and Apr 7, 2022, 6016 patients were assigned from 87 clinical sites in China. Included were patients undergoing primary percutaneous coronary intervention (PCI) within 48 hours of STEMI who were not on any anticoagulants, fibrinolytic therapy, or glycoprotein IIb/IIIa inhibitors. Altogether, 6016 patients (3009 to bivalirudin plus high-dose infusion after PCI and 3007 to heparin monotherapy) were included in the final analysis. The primary outcome composite of all-cause mortality and major bleeding at 30 days was significantly decreased in the bivalirudin group compared to the heparin monotherapy group (3.06% vs. 4.39%, respectively, hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.53-0.91, p=0.0070). Although stent thrombosis was more common in the heparin group (n=33, 1.10%) than bivalirudin (n=11, 0.37%), no significant differences occurred concerning reinfarction, stroke, or target vessel revascularization. Findings from this study suggest that treatment with bivalirudin plus high-dose infusion post-PCI may reduce mortality and major bleeding in patients with recent STEMI.

RELATED REPORTS

Wellness Check: Exercise

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

Empagliflozin use is associated with slower progression of chronic kidney disease

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myocardial infarctionBivalirudinbleedingbleeding riskcardiovascular diseasecardiovascular mortalitygastrointestinal bleedingheparinmyocardial infarctionpercutaneous coronary interventionpercutaneous coronary intervention (PCI)STEMIstroke
Previous Post

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease

Next Post

Supraphysiological perioperative oxygen associated with worse outcomes

RelatedReports

Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Preterm birth associated with cardiovascular risk factors in adolescence
Cardiology

Chlorthalidone is not superior to hydrochlorothiazide in preventing hypertension-related cardiovascular events

January 4, 2023
Next Post
Delays in surgical intervention do not increase odds of appendiceal perforation

Supraphysiological perioperative oxygen associated with worse outcomes

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

#VisualAbstract: Double sequential external defibrillation and vector-change defibrillation improve outcomes in patients with refractory ventricular fibrillation

ACP offers recommendations to improve the ACA, patient care

Parent decision making in poor-prognosis childhood cancer may extend beyond values and preferences

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options